沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析

doi:10.19803/j.1672-8629.20210154

摘要/Abstract

摘要： 目的评价沙库巴曲缬沙坦钠治疗高血压的有效性和安全性,为临床用药提供循证参考。方法检索PubMed、Embase、Medline、Cochrane图书馆、中国知网、万方数据,检索时限均为建库至2020年10月20日。收集沙库巴曲缬沙坦钠（试验组）与血管紧张素Ⅱ受体拮抗剂（ARB）类药物（对照组）的随机对照试验（RCT）数据,采用Cochrane系统评价员手册5.2.2推荐的偏倚风险评估工具对纳入文献质量进行评价,采用RevMan 5.3软件进行Meta分析。结果纳入8项RCT,共计4 313例患者。Meta分析显示,与对照组比较,试验组患者收缩压、舒张压、24 h动态收缩压、24 h动态舒张压均显著降低;血压控制率显著升高;患者咳嗽发生率显著高于对照组;2组之间其他不良事件发生率差异均无统计学意义。结论沙库巴曲缬沙坦钠可显著降低高血压患者的血压,总体安全性较好,但需注意患者服药后是否会引发咳嗽。

关键词: 沙库巴曲缬沙坦钠, 高血压, 血管紧张素Ⅱ受体拮抗剂, Meta分析

Abstract: Objective To evaluate the difference in effect and safety of sacubitril/valsartan sodium and angiotensin receptor blockers (ARB) in the treatment of hypertension. Methods Data on randomized controlled trials (RCT) of sacubatril/valsartan sodium (test group) versus angiotensin II receptor antagonist (ARB) (control group) was retrieved from PubMed, Embase, Medline, Cochrane Library , CNKI, Wanfang Database published from inception to October 20, 2020. The quality of the included literature was evaluated using the bias risk assessment tool recommended by Cochrane System Reviewer Manual 5.2.2, and the RevMan 5.3 software was used for Meta analysis. Results Eight RCT were included, involving 4 313 patients. Compared with ARB, sacubatril/valsartan sodium could more effectively reduce systolic blood pressure (msSBP), diastolic blood pressure (msDBP), ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure(maDBP). Sacubatril/valsartan sodium was basically as safe as ARB, but was more likely to cause cough. Conclusion sacubatril/valsartan sodium can significantly reduce blood pressure of patients with hypertension, but clinicians should be alert to any cough caused by this drug.

Key words: sacubatril/valsartan sodium, hypertension, angiotensin receptor blockers, Meta-analysis.

中图分类号:

R972.4

郑丽, 张续乾, 孙雪林, 丁辉华. 沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析[J]. 中国药物警戒, 2022, 19(10): 1118-1122.

ZHENG Li, ZHANG Xuqian, SUN Xuelin, DING Huihua. Effect and safety of sacubatril/valsartan sodium in the treatment of hypertension: a Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1118-1122.

参考文献

[1] LIU J.High blood pressure management: find out the right problems and make efforts accurately[J]. Chin J Health Manage(中华健康管理学杂志), 2019, 13(4): 273-276.
[2] MILLS KT, BUNDY JD, KELLY TN, et al.Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries[J]. Circulation, 2016, 134(6): 441-450.
[3] JAMES PA, OPARIL S, CARTER BL, et al.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5): 507-520.
[4] BRANDENBURG VM, ROCCA HB, MARX N.Herzinsuffizienztherapie bei Patienten mit Diabetes Sacubitril / Valsartan in patients with diabetes and heart failure[J]. Dtsch Med Wochenschr, 2016, 141(22): 1647-1649.
[5] VARDENY O, CLAGGETT B, KACHADOURIAN J, et al.Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the paradigm-hf trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)[J]. Circ Heart Fail, 2018, 11(4): e004745.
[6] DE VECCHIS R, ARIANO C, DI BIASE G, et al.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : a retrospective cohort study[J]. Herz, 2019, 44(5): 425-432.
[7] Chinese Medical Association, Journal of Chinese Medical Association, Chinese society of general practice, et al. Guidelines for primary diagnosis and treatment of hypertension (practice version, 2019)[J]. Chin J Gen Pract(中华全科医师杂志), 2019, 18(8): 723-731.
[8] WILLIAMS B, COCKCROFT JR, KARIO K, et al.Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension[J]. Hypertension, 2017, 69: 411-420.
[9] IZZO JL, ZAPPE DH, JIA Y, et al.Efficacy and safety of crystalline valsartan/sacubitril compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study[J]. J Cardiovasc Pharmacol, 2017(1): 1-5.
[10] WANG TD, TAN RS, LEE HY, et al.Effects of sacubitril/valsartan on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1): 32-41.
[11] SUPASYNDH O, WANG J, HAFEEZ K, et al.Efficacy and safety of sacubitril/valsartan compared with olmesartan in elderly Asian patients (>/=65 Years) with systolic hypertension[J]. Am J Hypertens, 2017, 30(12): 1163-1169.
[12] SCHMIEDER RE, WAGNER F, MAYR M, et al.The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study[J]. Eur Heart J, 2017, 38(44): 3308-3317.
[13] HUO Y, LI W, WEBB R, et al.Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2019, 21(1): 67-76.
[14] CHEUNG DG, AIZENBERG D, GORBUNOV V, et al.Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2018, 20(1): 150-158.
[15] RUILOPE LM, DUKAT A, BÖHM M, et al. Blood-pressure reduction with a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet, 2010, 375(9722): 1255-1266.
[16] HALL JE.The kidney, hypertension, and obesity[J]. Hypertension, 2003, 41(3): 625-633.
[17] ZHOU M, WANG H, ZENG X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10): 1145-1158.
[18] IADECOLA C, YAFFE K, BILLER J, et al.Impact of hypertension on cognitive function: a scientific statement from the american heart association[J]. Hypertension, 2016, 68(6): e67-e94.
[19] SEVERINO P, D'AMATO A, PUCCI M, et al. Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction[J]. Int J Mol Sci, 2020, 21(21): 8118.
[20] ITO S, SATOH M, TAMAKI Y, et al.Safety and efficacy of , a first-inclass angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38: 269-275.
[21] KORSHUNOV VA, QUINN B, FAIYAZ A, et al.Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains[J]. Br J Pharmacol, 2019, 176(15): 2795-2807.
[22] JORDAN J, STINKENS R, JAX T, et al.Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther, 2017 , 101(2): 254-263.
[23] YANDRAPALLI S, KHAN MH, ROCHLANI Y, et al.Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy[J]. Ther Adv Cardiovasc Dis, 2018, 12(8): 217-231.
[24] VECCHIS DR, SORECA S, ARIANO C.Anti-hypertensive effect of sacubitril/valsartan: a meta-analysis of randomized controlled trials[J]. Cardiol Res, 2019, 10(1): 24-33.
[25] LI Q, LI L, WANG F, et al.Effect and safety of in the treatment of hypertension: a meta-analysis of 9 RCT studies[J]. Medicine (Baltimore), 2019, 98(28): e16093.
[26] YAN JJ.Meta-analysis of the safety of sacubitril valsartan sodium in the treatment of essential hypertension[D]. Zhengzhou: Zhengzhou University, 2018.
[27] LI B, ZHAO Y, YIN B, et al.Safety of the neprilysin/renin-angiotensin system inhibitor[J]. Oncotarget, 2017, 47(8): 23-33.